Form 4: Heron Therapeutics, Inc. /De/ COO Reports Stock Transaction
Insider Transaction (Form 4)
Mark Earl Hensley, Chief Operating Officer of Heron Therapeutics, Inc. /De/, reported multiple transactions in common stock on July 31, 2026.
Summary
- Option exercise/conversion: acquired 11,769 Common Stock on July 31, 2026; holds 148,539 after (Direct).
- Option exercise/conversion: disposed of 11,769 Restricted Stock Units on July 31, 2026; holds 164,776 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Mark Earl Hensley — Officer (Chief Operating Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-07-31 | Option exercise/conversion | Common Stock | 11,769 | — | — | 148,539 |
| 2026-07-31 | Option exercise/conversion | Restricted Stock Units | 11,769 | — | — | 164,776 |
Key Dates
| Date | Description |
|---|---|
| 2026-07-31 | Option exercise/conversion (11,769 shares) |
| 2026-07-31 | Option exercise/conversion (11,769 shares) |
Keywords
insider transaction, Form 4, HRTX, HERON THERAPEUTICS, INC. /DE/, neutral, Mark Earl Hensley
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.